A new study by a Tulane University researcher casts doubt on a widely used shortcut in rectal cancer drug trials, raising concerns that some treatments may be fast-tracked for approval without evidence they help patients live longer.
FDA-backed metric used to determine effectiveness of rectal cancer drugs may be unreliable, says new study
